The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Using a novel machine learning model to analyze and predict the outcomes of patients with NDMM
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, describes a novel approach to predict the outcomes of patients with newly diagnosed multiple myeloma (NDMM) using a machine learning model. Dr Maura highlights the accuracy of this model and further explains its ability to individualize risk stratification for each patient. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
